Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RUBY Rubius Therapeutics (RUBY) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Rubius Therapeutics Stock (NASDAQ:RUBY) 30 days 90 days 365 days Advanced Chart Ad InvestorPlaceWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.Click here now to watch the full briefing and discover the steps to take today. Get Rubius Therapeutics alerts:Sign Up Key Stats Today's Range$0.06▼$0.0650-Day Range$0.02▼$0.0652-Week Range$0.00▼$0.38Volume755,858 shsAverage Volume1.15 million shsMarket Capitalization$5.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.Read More… What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.Click here now to watch the full briefing and discover the steps to take today. Receive RUBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RUBY Stock News HeadlinesFortnite Fans Only Want One Thing from the Rubius SkinSeptember 17, 2024 | msn.comHow to Get the Exclusive Rubius Fortnite DropSeptember 15, 2024 | msn.comA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…November 22, 2024 | Colonial Metals (Ad)‘Expats’ Star Ruby Ruiz to Lead James J. Robinson’s Directorial Debut ‘First Light’ (EXCLUSIVE)April 26, 2024 | yahoo.comVacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'March 11, 2024 | bizjournals.comRubius Therapeutics Inc RUBYNovember 5, 2023 | morningstar.comRUBY - Rubius Therapeutics, Inc.August 2, 2023 | uk.finance.yahoo.comNorth American Morning Briefing: Alphabet, -2-July 25, 2023 | morningstar.comSee More Headlines RUBY Stock Analysis - Frequently Asked Questions How were Rubius Therapeutics' earnings last quarter? Rubius Therapeutics, Inc. (NASDAQ:RUBY) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.01. When did Rubius Therapeutics IPO? Rubius Therapeutics (RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO. What other stocks do shareholders of Rubius Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rubius Therapeutics investors own include Meta Platforms (META), Sorrento Therapeutics (SRNE), Pfizer (PFE), Bristol-Myers Squibb (BMY), OPKO Health (OPK), Tesla (TSLA) and Athenex (ATNX). Company Calendar Last Earnings11/08/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:RUBY CUSIPN/A CIK1709401 Webwww.rubiustx.com Phone(508) 543-1720FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book0.34Miscellaneous Outstanding Shares90,480,000Free Float85,687,000Market Cap$5.16 million OptionableNot Optionable Beta2.59 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:RUBY) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rubius Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rubius Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
